Analytical Data
-
基因名
GRA3
- Application
-
别名
P30
-
种属
Toxoplasma gondii
-
表达系统
E. coli
-
标签
N- His
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
B6KEU8
-
表达区间
43-114aa
-
分子量
10.8 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GRA3 is a protein associated with the intracellular parasite Toxoplasma gondii, which is notorious for its ability to manipulate host immune responses and establish chronic infections. The GRA (genetic repertoire of Toxoplasma) family of proteins, including GRA3, plays a pivotal role in the biology of T. gondii, particularly in its interaction with host cells. GRA3 is believed to contribute to the formation of the parasitophorous vacuole, where the parasite resides and proliferates, as well as modulating host cell signaling pathways to enhance the pathogen's survival. Understanding the structure and function of GRA3 is crucial for elucidating the mechanisms of pathogenesis and host-parasite interactions. Research into GRA3 may unveil potential targets for therapeutic intervention, especially given the increasing concern surrounding chronic T. gondii infections and their implications for human health, particularly in immunocompromised individuals. Furthermore, uncovering the molecular details of GRA3 can provide insights into the evolutionary adaptations of T. gondii, enhancing our understanding of its complexity as a pathogen. Given the public health impact of T. gondii and the limited treatment options available, the study of GRA3 and its potential as a vaccine candidate or therapeutic target is a significant focus within parasitology and infectious disease research.












